ty.GREAT CAP,nice SS. also Impressive developments."Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity into the fourth quarter of 2016. The Company expects this will
support the completion and reporting of top line results for the Phase 2b Abili-T study of Tcelna in SPMS patients and the completion of the preclinical activities for OPX-
212 in NMO, as well as supporting general operations of the Company."
Clinical Highlights
As of April 30, 2015, approximately 75% of the patient visits have been completed in the Abili-T study in SPMS patients. The Abili-T clinical trial is a randomized, doubleblind,
placebo-controlled study being conducted at approximately 35 leading clinical sites in the U.S. and Canada. The trial is fully enrolled with 190 total subjects enrolled.
At a recent and regularly scheduled meeting, the independent Data and Safety Monitoring Board (DSMB) overseeing Opexa’s Abili-T trial recommended the trial continue as
planned based on the committee’s review of safety data from the trial. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for
Tcelna in SPMS.
Opexa was invited to present biomarker data on patients with neuromyelitis optica (NMO) at a scientific session and poster presentation at the 67 th American Academy of
Neurology (AAN) Annual Meeting in April.
Opexa continued IND enabling activities for OPX-212 (Opexa’s NMO therapeutic candidate), including advancing a bio-activity study and performing process development
work. IND submission for OPX-212 is expected in 2015.
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
